Related Experiment Video
Updated: Jun 2, 2026
Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization
Published on: November 17, 2023
Getting personal with prostate cancer: adding new pieces to an incomplete jigsaw puzzle
Ammad A Farooqi1, Shahzad Bhatti
1Institute of Molecular Biology and Biotechnology, University of Lahore, Lahore, Pakistan. ammadahmad638 @ yahoo.com
Abstract:
Prostate cancer is a multifaceted molecular anomaly that is insurmountable to date because of the orchestrated network of negative regulators that drive carcinogenesis. A substantial fraction of information has been added that gives yet an unclear snapshot of therapeutic interventions in prostate cancer. Increasing sophisticated interpretations point towards some important aspects of prostate cancer aggressiveness like microRNAs, prostate cancer stem cells and TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) refractoriness. In this review, we will evaluate the push and pull between oncomirs and tumor suppressors in tipping the scales of cancer. Furthermore, multicomponent rational drug designs with a claim to overcome stumbling blocks will be discussed. Translation of the outcomes achieved in the understanding of carcinogenesis at the patient's bedside is possibly the principal challenge in cancer research.
Insights
Prostate cancer
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Prostate cancer is a complex molecular disease driven by regulatory networks.
- Current therapeutic interventions offer an unclear outlook.
- Key factors in prostate cancer aggressiveness include microRNAs, cancer stem cells, and TRAIL refractoriness.
Purpose of the Study:
- To review the interplay between oncomirs and tumor suppressors in prostate cancer.
- To discuss rational drug designs for overcoming therapeutic challenges.
- To highlight the translation of research findings to clinical practice.
Main Methods:
- Literature review of current research on prostate cancer mechanisms.
- Analysis of the roles of microRNAs and cancer stem cells.
- Evaluation of drug design strategies targeting cancer pathways.
Main Results:
- Oncomirs and tumor suppressors play a critical role in cancer progression.
- Multicomponent drug designs show promise in addressing therapeutic resistance.
- Understanding carcinogenesis is crucial for patient treatment.
Conclusions:
- The balance between oncomirs and tumor suppressors is key in prostate cancer.
- Novel drug design approaches are needed to overcome treatment barriers.
- Bridging the gap between cancer research and patient care remains a significant challenge.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...